Organization | Clinique Saint Jean, Montpellier

Clinique Saint Jean, Montpellier Report issue

Academic/Hospital

Organization Overview

First Clinical Trial

2018

NCT03677323

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2024

Timeline

NOW

Now

Alternative names

Clinique Saint Jean, France | Clinique Saint Jean, Montpellier | Clinique Saint Jean Sud de France

Active Ingredients

Drugs in Other Trials (4)

droperidol (innovar) (1 trial)

levobupivacaine (chirocaine) (1 trial)

propofol (diprivan) (1 trial)

sufentanil (1 trial)

Indications

Overview

Highest Phase: Phase 0
# of Trials: 2
# of Trial APIs: 4